Wednesday 24 January 2018 | ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares
The December 2017 edition of the UK Investor Magazine is now live: What will Father Christmas be putting in the stockings of the writers of ShareProphets, nine share tips , plus sexism at the BBC
The Mail on Sunday headline says it all " Brexit fears are diverting cash from vital cancer battle say drug firms." That sod Boris Johnson and the witch Priti Patel - now they are causing more cancer patients to die. Bastards! Er....
The big pharmaceutical companies have traditionally been a fairly safe bet for a steady source of income over the years, and through the peaks and troughs in the markets.
Hello Share Shapers. Every so often I look at that great British pharmaceutical giant, GlaxoSmithKline (GSK) and I usually notch it up as a buy. Despite the fact that it has not been quite as successful a punt as I had hoped, I am still well up on my three year old purchase. The dividend, which I have at nearly 5% is also useful. And I was gratified that it was one of the perkiest Footsie risers on Friday.
Hello Share Punchers. I’ve just heard on the BBC more woes facing British hospitals. It does seem that most of them now have no slack and routine operations keep being put off, with nowhere to send many patients once beyond the surgeon’s knife.
It is great to see that one of the UK's largest companies, GlaxoSmithKline (GSK) has a new CEO who has a cracking CV and and has without doubt been appointed on merit. Oh... and she wears a skirt, that is to say that she is a woman, Emma Walmsley. I wish her well. Emma demonstrates a couple of things which will horrify the liberal left.
With uncertainty over Brexit and possible market turmoil around this event, and assuming you’re not planning to move to cash, now would seem like a good time to add some defensive shares to your portfolio.
I hope you have a happy and healthy New Year. Though, especially if you are of a certain age, I fear the odds are against it. My Christmas cards usually contain letters from old friends and relatives. And I was shocked to learn that one of them had almost lost her sight, another is on crutches awaiting knee transplants, another has breast cancer and so on.
Hello Share Trippers. Oh dear! The price of crude oil drops to less than 40 dollars a barrel.That’s really nasty and we can blame OPEC for refusing to cut down on the amber nectar it has for sale.
The recent big drops in many leading stock market indices, including the FTSE100, is giving an opportunity to pick some stocks up at a bargain price. I think that GlaxoSmithKline (GSK) definitely falls into that category and its current share price of around 1285p – the lowest levels since mid-2011 – offers a great long term buying opportunity for this FTSE100 listed pharmaceutical company.
After some careful thought I have selected GlaxoSmithKline (GSK) as one of just two of my Prime Share Selections for 2015. Being honest, I find it difficult to pick two which really should be the best of all shares, but I am fairly confident GlaxoSmithKline will perform well in 2015.
GlaxoSmithKline (GSK) has recently announced that it has failed to sell its established products portfolio. This is basically a bunch of North American and European drugs that have recently lost their patent protection.
Hello Share Pounders. At the risk of sounding again like a soft goody goody (TW Note - perish the thought), I want to commend to you the warm feeling that can be achieved by investing in big pharma companies.
It’s been a torrid year for GlaxoSmithKline’s (GSK) share price. From a year high of 1706p, it recently fell to a low of 1296.p. However there was some much needed cheer yesterday, when the shares, trading at around 1330p, were lifted to over 1400p briefly, before closing at 1385.5p. The catalyst? Publication of its results at 12 o’clock which beat expectations.
Ebola is certainly everywhere on the news at the moment. The epidemic continues to spread like wildfire, and more people are dying all the time. Thankfully, GlaxoSmithKline (GSK) is continuing its work on a vaccine which should help stem the spread. Today it issued a press statement, opening with the following:
The FTSE took quite a hit yesterday. It closed down by 1.04% at 6495.58. Yet there is good news- I believe there are a number of buying opportunities around at the moment! For the long term investor a general market sell off should be viewed as an opportunity not a cause for alarm. So here are two stocks that I am nowlooking to add to thanks to the market wobble.
GlaxoSmithKline (GSK) shares are currently trading at 1457p on a PE of 13.1 and a dividend yield of 5.35%. I’ve only fairly recently bought into the company, here is a table at between 1379p and 1556.6p, So I am not exactly quids in yet but this is a long term play.
The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self. Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that “there will always be a Glaxo”; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?
Hello Share Fans: I'm in a strange position for me. I have a few thousand quid in my ISA which I need to invest. I think I might take a look at GlaxoSmithKline (GSK).
The latest information and news emerging from GlaxoSmithKline (GSK) is of encouragement to investors generally but to dividend investors most particularly. Although the company is one of the stock markets dividend yield staple, with a long established reputation for cash generation, a glance at the trends in its cash flow statements is a bit disconcerting.
Medical matters are on my mind as I have the Norovirus. But it takes more than that to stop me writing about companies but naturally my mind turns to drugs. Well I was a young man in the sixties – the 1960s not the 1860s before you ask. Talking of ancient history, the market long ago abandoned the assumption that GlaxoSmithKline (GSK) would automatically build a pathway for shareholders to a starlight future of endless profits and earnings growth, by simply spending 15% of its sales revenue on R&D, and turning that into an approved blockbuster therapy every few years. In truth, costs rose and progress became more difficult – the return on R&D capital was not acceptable.
Search ShareProphets |
Recent Comments |